CHP1 and nonpapillary renal cell carcinoma: Quantitative assessment with H-scores analyzed using Visiopharm software confirmed this trend, showing significantly reduced CHP1 expression in both ccRCC tissues overall and in late-stage tumors (Figure 4D).